<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321709</url>
  </required_header>
  <id_info>
    <org_study_id>TDR11407</org_study_id>
    <secondary_id>2014-001690-13</secondary_id>
    <secondary_id>U1111-1154-6184</secondary_id>
    <nct_id>NCT02321709</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the tolerability and safety of SAR113244 in male and female lupus patients after
      every 4 (Q4) weeks repeated ascending subcutaneous doses of SAR113244.

      Secondary Objectives:

      To assess in male and female lupus patients:

        -  The pharmacokinetics of SAR113244.

        -  The pharmacodynamics of SAR113244 for the following disease-related parameters:

             -  Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus
                Erythematosus Disease Activity Index (SELENA-SLEDAI) score, British Isles Lupus
                Assessment Group (BILAG) score (if applicable), BILAG-Based Composite Lupus
                Assessment (BICLA) (if applicable), systemic lupus erythematosus responder index
                (SRI) (if applicable), Lupus-quality of life (QoL) and Functional Assessment of
                Chronic Illness Therapy (FACIT)-Fatigue, anti-double stranded deoxyribonucleic acid
                antibody (anti-dsDNA Ab) and anti-nuclear antibody levels (ANA) and plasma
                complement levels (C3, C4), erythrocyte sedimentation (SED) rate and C-reactive
                protein.

             -  Peripheral blood B and T cells subsets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of screening to end of study per subject is 20 weeks with post-study
      observation on Day 226 for anti-drug antibody assessment (for patients with positive
      anti-drug antibody at end of study only).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events and treatment-emergent adverse events</measure>
    <time_frame>Up to 16 weeks after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in physical examination, body weight, vital signs and laboratory parameters</measure>
    <time_frame>Up to 16 weeks after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability (erythema, swelling, degree of itching, and present pain intensity at injection site by measuring diameter and qualitative assessment)</measure>
    <time_frame>Up to 16 weeks after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - maximum concentration (Cmax)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - time of maximum concentration (Tmax)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - area under curve 0-4 weeks (AUC0-4w)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - time of the last point with quantifiable concentration (tlast) and terminal elimination half-life (t1/2z)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - lowest concentration of drug before the next dose (Ctrough)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - apparent total body clearance (CLss/F)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter - absorption-dependent apparent volume of distribution at steady state (Vss/F)</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-SAR113244 antibody titers</measure>
    <time_frame>Up to D226 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter changes</measure>
    <time_frame>Up to D113 after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters: peripheral blood B and T cells subsets</measure>
    <time_frame>Up to D85 after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>SAR113244 cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR113244 cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR113244 cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR113244</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>SAR113244 cohort 1</arm_group_label>
    <arm_group_label>SAR113244 cohort 2</arm_group_label>
    <arm_group_label>SAR113244 cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>SAR113244 cohort 1</arm_group_label>
    <arm_group_label>SAR113244 cohort 2</arm_group_label>
    <arm_group_label>SAR113244 cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients, between 18 and 75 years of age, inclusive.

          -  Clinical diagnosis of systemic lupus erythematosus (SLE) by American College
             Rheumatology criteria.

          -  Autoantibody-posititve.

          -  On active and stable SLE disease.

        Exclusion criteria:

          -  Pregnant and nursing.

          -  Have received treatment with investigational drugs in the 4 months prior to the
             screening or 5 half-lives of the drug, whichever is longer.

          -  Have received intravenous or oral cyclophosphamide within 180 days of Day 0. Severe
             active lupus nephritis or chronic renal insufficiency.

          -  Active or chronic, severe neuropsychiatric lupus.

          -  Acute, recent (within 4 weeks of screening), chronic or frequently recurring
             infection(s), except minor infection.

          -  Have current drug or alcohol abuse or dependence.

          -  Have a historically positive test or test postitive at screening for HIV, hepatitis B,
             or hepatitis C.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

